Melior Discovery partnering with us

Melior Discovery works collaboratively with its pharmaceutical and biotechnology partners through the entire drug discovery and development process. The scope, goals and end-points of each study are discussed thoroughly and frequently with the client. This collaborative approach results in a customized program that is designed to meet the partner's specific needs.

Melior will work with clients to establish collaborations and partnerships that address specific stages of their drug discovery and development needs including:

• Early stage: Ideal when multiple leads must be narrowed down to a select few compounds suitable to move into development. With the potential reduction of false negatives, Melior's clients benefit from a greater likelihood of identifying compounds with greater efficacy in alternative indications.

• Late stage: Allows for co-development and risk sharing collaboration structures. In this scenario, Melior works with a partner's late stage drug candidate that may previously have failed in efficacy testing and utilizes the theraTRACE® platform to identify novel indications for the compound. In addition to the theraTRACE® discovery platform, Melior offers partners additional drug discovery capabilities, including individualized efficacy models and pharmacokinetic (PK) and maximum tolerated dose (MTD) evaluations to meet the diverse drug development needs of its partners.

For more information about our own development programs, please visit meliorpharmaceuticals.com.

For additional information, contact:
Andrew G. Reaume
President and CEO, Co-Founder
(610) 280-0633

Dr. Zahed Subhan
Business Development Consultant
(610) 280-0633